Carisma Therapeutics
Delivering macrophage biology, chimeric antigen receptor engineering and adoptive cellular therapy for the treatment of human disease.
Launch date
Employees
Market cap
CAD57.8m
Enterprise valuation
CAD14m (Public information from Sep 2024)
Share price
$0.981 CARM
Philadelphia Pennsylvania (HQ)
Authorizing premium user...